Congress offers tax breaks for drug-research startups fighting fentanyl crisis
H.R. 4573 — Innovate to Save Lives Act · Filed by Joe Neguse (D-CO) · 5 cosponsors · Introduced Jul 21, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a new 10% federal tax credit for small businesses that conduct research aimed at mitigating drug threats—specifically fentanyl, methamphetamine, emerging drugs designated by federal authorities, and fentanyl-related substances. The credit applies to qualified research expenses, including work on treatment, prevention, diversion, and intervention strategies, but excludes most clinical research unless it meets NIH guidelines. A GAO report is required five years after enactment to track credit usage and research types.
Why we flagged it
The bill's operative mechanism is a targeted tax credit for small-business research into drug-threat mitigation. It is a straightforward incentive structure, not a subsidy, immunity grant, or deregulation.
What the text implies
- The definition of 'fentanyl-related substance' is chemical-structure-based and may capture novel synthetic variants faster than DEA scheduling, potentially creating a moving target for research compliance.
- Small businesses may lack the infrastructure to conduct NIH-compliant clinical research, limiting the credit's utility for the most impactful drug-mitigation work and concentrating benefits among better-resourced firms.
The full analysis lists 4 implications of this text.
Who stands to gain
small businesses conducting pharmaceutical or biotech research; contract research organizations (CROs) serving small-business clients; research-stage biotechnology firms focused on addiction treatment or drug diversion